ROBERT J. MORE - 30 May 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Director
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol: VIR
Transactions as of: 30 May 2024
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2024, 12:08:28 UTC
Previous filing: 31 May 2024
Next filing: 02 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+8,000	+21%	$0.000000	46,683	30 May 2024	Direct
holding	VIR	Common Stock						495,890	30 May 2024	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+16,000		$0.000000	16,000	30 May 2024	Common Stock	16,000	$10.39	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.